Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taro Pharmaceutical Industries and NextWave Pharmaceuticals have announced that Taro's US subsidiary and NextWave have entered into an agreement to co-promote Ovide lotion, 0.5% in the US.
Subscribe to our email newsletter
Under the agreement Taro will retain all responsibility for the manufacture, distribution and sales of Ovide. Ovide is a prescription drug approved by the FDA for the treatment of head lice.
In August 2008, NextWave’s pediatric specialty sales force will begin promoting Ovide to approximately 6,000 pediatricians and other appropriate healthcare professionals. Taro USA’s branded division, TaroPharma, and the NextWave sales force combined will reach approximately 10,000 practicing pediatricians.
Barrie Levitt, chairman of Taro, said: “We are pleased to partner with NextWave and more than double our presence among key pediatricians that treat patients who suffer from head lice.”